JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Anderson, C. J.
Right arrow Articles by McCarthy, D. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Anderson, C. J.
Right arrow Articles by McCarthy, D. W.
Journal of Nuclear Medicine Vol. 42 No. 2 213-221
© 2001 by Society of Nuclear Medicine


CLINICAL INVESTIGATIONS

64Cu-TETA-Octreotide as a PET Imaging Agent for Patients with Neuroendocrine Tumors

Carolyn J. Anderson, Farrokh Dehdashti, P. Duffy Cutler, Sally W. Schwarz, Richard Laforest, Laura A. Bass, Jason S. Lewis and Deborah W. McCarthy

Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri

64Cu (half-life, 12.7 h; ß+, 0.653 MeV [17.4%]; ß-, 0.579 MeV [39%]) has shown potential as a radioisotope for PET imaging and radiotherapy. 111In-diethylenetriaminepentaacetic acid (DTPA)-D-Phe1-octreotide (OC) was developed for imaging somatostatin-receptor–positive tumors using conventional scintigraphy. With the advantages of PET over conventional scintigraphy, an agent for PET imaging of these tumors is desirable. Here, we show that 64Cu-TETA-OC (where TETA is 1,4,8,11-tetraazacyclotetradecane-N,N',N'',N'''-tetraacetic acid) and PET can be used to detect somatostatin-receptor–positive tumors in humans. Methods: Eight patients with a history of neuroendocrine tumors (five patients with carcinoid tumors and three patients with islet cell tumors) were imaged by conventional scintigraphy with 111In-DTPA-OC (204–233 MBq [5.5–6.3 mCi]) and by PET imaging with 64Cu-TETA-OC (111 MBq [3 mCi]). Blood and urine samples were collected for pharmacokinetic analysis. PET images were collected at times ranging from 0 to 36 h after injection, and the absorbed doses to normal organs were determined. Results: In six of the eight patients, cancerous lesions were visible by both 111In-DTPA-OC SPECT and 64Cu-TETA-OC PET. In one patient, 111In-DTPA-OC showed mild uptake in a lung lesion that was not detected by 64Cu-TETA-OC PET. In one patient, no tumors were detected by either agent; however, pathologic follow-up indicated that the patient had no tumors. In two patients whose tumors were visualized with 111In-DTPA-OC and 64Cu-TETA-OC, 64Cu-TETA-OC and PET showed more lesions than 111In-DTPA-OC. Pharmacokinetic studies showed that 64Cu-TETA-OC was rapidly cleared from the blood and that 59.2% ± 17.6% of the injected dose was excreted in the urine. Absorbed dose measurements indicated that the bladder wall was the dose-limiting organ. Conclusion: The high rate of lesion detection, sensitivity, and favorable dosimetry and pharmacokinetics of 64Cu-TETA-OC indicate that it is a promising radiopharmaceutical for PET imaging of patients with neuroendocrine tumors.

Key Words: 64Cu • octreotide • PET • 111In







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2001 by the Society of Nuclear Medicine.